Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elbasvir/grazoprevir - Merck and Co

Next Previous
X
Search
Drug Profile

Elbasvir/grazoprevir - Merck and Co

Alternative Names: Elbasvir and grazoprevir; Grazoprevir/elbasvir; MK-5172/MK-8742; MK-5172A; MK-8742/MK-5172; ZEPATIER

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class Amides; Antivirals; Benzoxazines; Carbamates; Carboxylic acids; Cyclopropanes; Heterocyclic compounds with 4 or more rings; Imidazoles; Indoles; Macrocyclic compounds; Pyrrolidines; Quinoxalines; Small molecules; Sulfones
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 31 Dec 2022 University of Pennsylvania and Merck completes a phase I/II trial for Hepatitis C in USA (NCT03724149)
  • 28 Sep 2021 No development reported - Phase-III for Hepatitis C (Treatment-naive) in Russia (PO) (NCT02251990)
  • 28 Sep 2021 No development reported - Phase-III for Hepatitis C (Treatment-naive) in South Korea (PO) (NCT02251990)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top